| Literature DB >> 30486479 |
Yurngdong Jahng1, Jae Gyu Park2.
Abstract
Diarylheptanoids are a family of plant secondary metabolites with a 7 carbon skeleton possessing two phenyl rings at the 1- and 7-positions. They can be subdivided into acyclic and cyclic diarylheptanoids where the latter are further divided into meta,meta-bridged biphenyls ([7.0]metacyclophanes) and meta,para-bridged diphenyl ether heptanoids (oxa[7.1]metapara-cyclophanes). Since the isolation of curcumin from the rhizomes of turmeric (Curcuma longa) in 1815 which was named curcumin, a variety of diarylheptanoids have been isolated from a number of plant families such as Aceraceae, Actinidiaceae, Betulaceae, Burseraceae, Casuarinaceae, Juglandaceae, Leguminosae, Myricaceae, and Zingiberaceae. Earlier studies on these diarylheptanoids have been summarized on several occasions, of which the main themes only focus on isolation, structure elucidation, and the biological properties of linear types. Only a few have covered cyclic diarylheptanoids and their chemical synthesis has been covered lastly by Zhu et al. in 2000. The present paper has, therefore, covered recent progress in cyclic diarylheptanoids focusing on the isolation, structural and biological features, and chemical synthesis.Entities:
Keywords: biphenyl heptanoid; diarylheptanoid; diphenyl ether heptanoid; total synthesis
Mesh:
Substances:
Year: 2018 PMID: 30486479 PMCID: PMC6321387 DOI: 10.3390/molecules23123107
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Occurrence of diarylheptanoids in plants reported in the literature.
| Family | Genus | Diarylheptanoids | Reference(s) | ||
|---|---|---|---|---|---|
| Linear (Type I) | Biphenyl (Type II) | Diphenyl Ether (Type III) | |||
| Aceraceae |
| + | + | + | [ |
| Actinidiaceae |
| − | − | + | [ |
| Betulaceae |
| + | + | + | [ |
|
| + | + | + | [ | |
|
| − | + | − | [ | |
|
| − | + | − | [ | |
|
| − | + | − | [ | |
|
| + | + | + | [ | |
| Burseraceae |
| − | + | + | [ |
|
| − | − | + | [ | |
| Casuarinaceae |
| − | + | − | [ |
| Juglandaceae |
| + | − | + | [ |
|
| + | + | + | [ | |
|
| − | + | + | [ | |
|
| − | − | + | [ | |
|
| + | + | + | [ | |
| Myricaceae |
| − | + | + | [ |
|
| + | + | + | [ | |
| Rubiaceae |
| − | + | − | [ |
| Zingiberaceae |
| + | − | − | [ |
|
| + | − | − | [ | |
Derivatives of alnusonol (5a) and alnusdiol (7a), and their stereochemistry.
| R1 | R2 | R3 | X1 | X2 | X3 | X4 | X5 | Chiral Axis | Reference and Biological Activity | |
|---|---|---|---|---|---|---|---|---|---|---|
| alnusonol ( | H | H | H | H,H | - | H,H | H,OH ( | H | α-glucosidase inhibitor [ | |
| alnusdiol ( | H | H | H | H,H | OH ( | H,H | H,OH ( | H | a | [ |
|
| H | H | H | H,H | - | H,H | H,OH | OH | [ | |
|
| H | H | H | H,H | - | H,OH | O | H | anti-adipogenic activity [ | |
| giffonin L a ( | H | H | H | H,OH ( | OH ( | H,OH ( | H,H | OH ( | [ | |
| giffonin M ( | H | H | H | H,H | - | H,OH ( | H,H | OH ( | [ | |
| giffonin N ( | H | H | H | H,H | - | H,OH ( | H,H | [ | ||
| giffonin O ( | H | H | H | H,OH ( | H | O | H,OH ( | OH ( | [ | |
| giffonin P a ( | H | H | H | H,OH ( | OH ( | H,OH | H,OH ( | OH ( | [ | |
| giffonin T ( | H | R′ b | H | H,H | - | H,OH ( | H,OH ( | OH ( | a | [ |
| giffonin U ( | H | H | H | O | OH ( | H,OH ( | H,OH ( | OH ( | a | [ |
| carpinontriol A ( | H | H | H | H,OH ( | - | H,H | H,OH ( | OH ( | [ | |
| carpinontriol B ( | H | H | H | H,H | - | H,OH ( | H,OH ( | OH ( | a | [ |
|
| OH | CH3 | H | H,H | - | H,H | H,H | H | [ | |
| aceroside XI c ( | H | H | R′ b | H,H | - | H,H | H,H | H | [ | |
| acerogenin E d ( | H | H | H | H,H | - | H,H | H,H | H | NO production inhibitor | |
| acerogenin K ( | H | H | H | H,H | OH | H,H | H,H | H | NO production inhibitor | |
| ostryopsitriol ( | H | H | H | H,OH | OH | H,H | H,OH | H | [ | |
| betulatetraol ( | H | H | H | H,OH | OH | H,H | H,OH | OH | [ |
a Giffonin A–K, Q, R, and S are diphenyl ether heptanoids (vide infra). b R’ = β-d-glucopyranosyl. c Aceroside I–X are cyclic diphenyl ether heptanoids (vide infra). d Acerogenins A–D, F, H–J, L, and M are cyclic diphenyl ether heptanoids (vide infra).
The derivatives of myricanone (11a) and their biological properties.
| Compound | R1 | R2 | R3 | R4 | X1 | X2 | X3 | Reference(s) and Biological Properties |
|---|---|---|---|---|---|---|---|---|
| OH | CH3 | H | H | H | H | H | cytotoxicity [ | |
|
| CH3 | H | H | H | H | H | DPPH radical scavenging activity (49.09%) [ | |
| CH3 | COCH3 | H | H | H | H | DPPH radical scavenging activity (41.16%) [ | ||
|
| CH3 | H | H | H | H | H | [ | |
| OCH3 | H |
| H | H | H | H | [ | |
|
|
| CH3 | H | H | H | H | H | [ |
| myricananin C ( | H | H | H | H | H | H | H | NO release inhibition (IC50 = 64.51 μM) [ |
| myricananin E ( | OH | CH3 | H | OH | H | H | OCH3 | [ |
| myricananone ( | OH | CH3 | H | H | OH | H | H | [ |
|
| H | CH3 | H | H | H | H | H | [ |
|
| OH | CH3 | H | H | H | H | OH | anti-tubercular activity (IC50 = 35.8 μg/mL) [ |
a Value is the concentration (Mol ratio/TPA) needed to inhibit 50% of positive control activated with TPA.
The derivatives of myricanol (12a) and their biological properties.
| Compound | R1 | R2 | R3 | R4 | X1 | X2 | X3 | X4 | Reference(s) and Biological Properties |
|---|---|---|---|---|---|---|---|---|---|
| myricanol ( | OH | CH3 | H | H | H | H | OH ( | H | [ |
| juglanin B ( | H | H | H | H | H | H | OH ( | H | cytotoxic (HT-29) [ |
| salicireneol A ( | H | β-Glc | H | H | H | H | OH ( | H | [ |
| salicireneol B ( | H | H | β-Glc | OH | H | H | OH ( | H | [ |
| myricananin A ( | H | H | H | H | H | H | OH ( | OH ( | NO release inhibitor (IC50 = 45.32 μM) [ |
| myricananin B ( | OH | CH3 | H | H | H | H | OH ( | OH ( | [ |
| myricananin F ( | H | H | H | H | H | OH | H | H | [ |
| myricananin G ( | OH | CH3 | CH3 | H | H | H | OH ( | OH ( | [ |
| myricananin H ( | OCH3 | CH3 | CH3 | H | H | H | OH ( | OH ( | [ |
| salicimeckol ( | CH3 | H | H | OH | H | OH ( | H | [ | |
|
| CH3 | H | H | H | H | OH ( | H | anti-allergic activity [ | |
|
|
| CH3 | H | H | H | H | OH ( | H | [ |
|
|
| CH3 | H | H | H | H | OH ( | [ | |
|
|
| CH3 | H | H | H | H | OH ( | [ |
The acerogenins with diphenyl ether heptanoid skeleton and their biological properties.
| Compound | R1 | R2 | R3 | X1 | X2 | X3 | X4 | Reference and Biological Properties |
|---|---|---|---|---|---|---|---|---|
| acerogenin A ( | H | H | H | H,H | H,H | H,OH ( | H,H | anti-inflammatory (IC50 = 0.32 mg/ear) [ |
| acerogenin B ( | H | H | H | H,H | H,OH | H,H | H,H | cytotoxicity (IC50 = 25.1 μM) of ( |
| acerogenin C ( | H | H | H | H,H | H,H | O | H,H | antibacterial and neuroprotective [ |
| acerogenin D ( | H | H | H | H,H | H,OH | O | H,H | radical scavenging activity (IC50 = 40 μM) [ |
| acerogenin F ( | H | H | H | H,H | H,H | H,OH ( | H,OH ( | [ |
| acerogenin H ( | H | H | H | O | H,H | H,OH | H,H | [ |
| acerogenin I ( | H | H | H | H,H | H,OH | H,H | H,OH | [ |
| acerogenin J ( | H | H | H | H,H | H,H | H,OH ( | H,OH ( | [ |
| acerogenin L ( | H | H | H | H,H | O | H,H | H,H | [ |
| acerogenin M ( | H | H | H | O | H,OH | H,H | H,H | antitumor promoting activity [ |
| pterocarine ( | H | OH | H | H,H | O | H,H | H,H | cytotoxic against K562 (51% @100 μg/mL) [ |
| galeon ( | H | OCH3 | H | H,H | O | H,H | H,H | [ |
| 10-hydroxygaleon ( | H | OCH3 | H | H,OH | O | H,H | H,H | [ |
|
| H | OCH3 | H | H,H | H,OH ( | H,H | H,H | [ |
| myricatomentogenin ( | H | OCH3 | OH | H,H | O | H,H | H,H | [ |
| jugcathanin (juglanin A, | CH3 | OCH3 | OH | H,H | O | H,H | H,H | cytotoxicity [ |
| platycarynol ( | CH3 | OCH3 | H | H,H | H,OH ( | H,H | H,H | [ |
| aceroside B1 ( | β- | H | H | H,H | H,OH ( | H,H | H,H | [ |
| aceroside B2 ( | β- | H | H | H,H | H,OH ( | H,H | H,H | [ |
| aceroside I ( | β- | H | H | H,H | H,H | H,OH ( | H,H | [ |
| aceroside II ( | H | H | H | H,H | H, O-β- | H,H | H,H | [ |
| aceroside III ( | H | H | H | H,H | H,H | H,Y c | H,H | radical scavenging activity (IC50 = 40 μM), osteogenic activity [ |
| aceroside IV ( | β- | H | H | H,H | H,H | O | H,H | [ |
| aceroside V ( | β- | H | H | H,H | H,OH | O | H,H | [ |
| aceroside VI b ( | H | H | H | H,H | H,H | H, | H,H | [ |
| 9-oxoacerogenin A ( | H | H | H | H,H | O | H,OH | H,H | anti-melanogenesis (17.6% @100 μM) [ |
| maximowicziol A ( | H | H | H | H,H | H,OH ( | H,H | H,OH ( | [ |
|
| CH3 | OCH3 | OH | H,H | H,OH | H,H | H,H | cytotoxic against A549 (IC50 = 11.5 μg/mL) [ |
| jugsigin A ( | H | H | OH | H,H | H,OH ( | H,H | H,H | cytotoxic against HT-29 [ |
| 2-methylacerogenin A ( | CH3 | H | H | H,H | H,H | H,OH ( | H,H | [ |
a Acerogenin E (5l) and K (7h) are biphenyl heptanoids, acerogenin G is a linear diarylheptanoid, 7-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)heptan-3-one [117]. b At present, 11 acerosides have been reported: acerogenins VII and VIII are 3-O-β-d-glucopyranosides of linear diarylheptanoid, 1,7-di(4-hydroxyphenyl)heptan-3-ol [118], acerosides IX and X are β-d-glucopyranosides of linear diarylheptanoid, 1,7-di(4-hydroxyphenyl)heptan-3-one [117], and aceroside XI is 5k. c Y = O-β-d-Api-(1->6)-β-d-Glc.
Diaryl ether heptenoids, giffonin A–K, Q, R, and S.
| R1 | R2 | R3 | X1 | X2 | X3 | Reference | |
|---|---|---|---|---|---|---|---|
| giffonin A ( | OCH3 | OH | OCH3 | - | - | H | [ |
| giffonin B ( | OCH3 | OH | OCH3 | - | - | OH ( | [ |
| giffonin C ( | OCH3 | OH | OCH3 | H | H,OH ( | H | [ |
| giffonin D ( | OCH3 | OH | OCH3 | H | O | H | [ |
| giffonin E ( | OCH3 | OH | OCH3 | OH ( | H,H | H | [ |
| giffonin F ( | OCH3 | OH | OCH3 | OH ( | O | H | [ |
| giffonin G ( | OCH3 | OH | OCH3 | - | H,OH ( | H | [ |
| giffonin H ( | H | OH | OCH3 | - | H,OH ( | H | [ |
| giffonin J a ( | OCH3 | OH | OCH3 | H | H,OH ( | OH ( | [ |
| giffonin K ( | OCH3 | OH | OCH3 | - | H,OH ( | OH ( | [ |
| giffonin Q ( | H | H | H | - | O | H | [ |
| giffonin R ( | H | H | OH | - | O | H | [ |
| giffonin S ( | H | OCH3 | OH | - | O | H | [ |
a Giffonin I, L–P, T, and U are biphenyl heptanoids (vide supra).
Scheme 1Propsed biosynthetic pathway for the linear and cyclic diaryl ether heptanoids.
Scheme 2Retrosynthetic analysis for the synthesis of acerogenins.
Optimization of reaction conditions.
| Ligand | Base | Yield (%) a | Ratio (pR : pS) b |
|---|---|---|---|
|
| Cs2CO3 | 18 | 38: 62 |
|
| Cs2CO3 | 22 | 44: 56 |
|
| Cs2CO3 | 41 | 68: 32 |
|
| Cs2CO3 | 34 | 57: 43 |
|
| K3PO4 | 39 | 72: 28 |
a Isolated yield (average of three trials). b Determined by HPLC.
Screening reaction conditions for cyclization of linear diarylheptanoid 88b.
| Solvent | Base (aq. Solution) | Yield (%) b) | Er c) |
|---|---|---|---|
| toluene (5 mL) | 20% CsOH | 47 | 87: 13 |
| DMF (5 mL) | 20% CsOH | 90 | 50: 50 |
| xylene (5 mL) | 20% CsOH | 47 | 82: 18 |
| toluene (5 mL) | 20% CsF | <10 | 69: 31 |
| toluene (5 mL) | 20% KOH | 17 | 64: 36 |
| toluene (5 mL) | 20% CsOH | 46 | 89: 11 |
| toluene (5 mL) d) | 20% CsOH | 80 | 91: 9 |
| toluene (5 mL) d) | 20% CsOH | 47 | 91.5: 8.5 |
a) Reagents and reaction conditions: 88b (37.5 mg, 0.1 mmol), PTC (10 mol%), base (15 equiv), rt, 40 h. b) Isolated yields. c) Determined by high-performance liquid chromatography (HPLC) analysis. d) 20 mol% PTC used.